Home > Annual Financials > SUPRIYA LIFESCIENCE

SUPRIYA LIFESCIENCE Financial Statement Analysis
[BOM: 543434|NSE : SUPRIYA]

The Revenues of SUPRIYA LIFESCIENCE have decreased by -13.04% YoY .
The Earnings Per Share (EPS) of SUPRIYA LIFESCIENCE has decreased by -40.83 % YoY.
REVENUES
OPERATING MARGIN
PROFIT AFTER TAX
EPS
ROCE

SUPRIYA LIFESCIENCE Last 5 Annual Financial Results
[BOM: 543434|NSE : SUPRIYA]

StandaloneMar2023
Mar2022
Mar2021
Mar2020
Mar2019
Revenues ₹461 Cr₹530 Cr₹391 Cr₹312 Cr₹278 Cr
Expenses ₹332 Cr₹316 Cr₹218 Cr₹213 Cr₹213 Cr
Operating Profit (Excl OI) ₹128 Cr₹214 Cr₹173 Cr₹98 Cr₹64 Cr
Other Income ₹9.99 Cr₹7.58 Cr₹5.01 Cr₹11 Cr₹8.33 Cr
Interest ₹3.13 Cr₹4.20 Cr₹4.08 Cr₹6.85 Cr₹10 Cr
Depreciation ₹12 Cr₹10 Cr₹6.76 Cr₹6.38 Cr₹5.44 Cr
Profit Before Tax ₹123 Cr₹207 Cr₹167 Cr₹96 Cr₹57 Cr
Profit After Tax ₹90 Cr₹152 Cr₹124 Cr₹73 Cr₹39 Cr
Consolidated Net Profit ₹90 Cr₹152 Cr₹124 Cr₹73 Cr₹39 Cr
Earnings Per Share (Rs)₹11.16₹18.86₹16.89₹50.15₹26.93
PAT Margin (%)17.4025.8028.6820.4112.27
ROE(%)13.6634.3459.1760.4253.11
ROCE(%)18.7243.3460.1249.6736.52
Total Debt/Equity(x)0.020.030.260.550.96

Key Financials

Market Cap : ₹ 3,301.7 Cr
Revenue (TTM) : ₹ 554.5 Cr
Net Profit(TTM) : ₹ 120.4 Cr
EPS (TTM) : ₹ 15.0
P/E (TTM) : 27.4

Industry Peers & Returns1W1M1Y
SUPRIYA LIFESCIENCE -0.1% 15.3% 93.1%
SUN PHARMACEUTICAL INDUSTRIES 0.3% -7.5% 53.9%
CIPLA 1.1% -4.8% 56.4%
DR REDDYS LABORATORIES 1.6% 1.6% 27.6%
ZYDUS LIFESCIENCES 5.2% -0.2% 90.1%
DIVIS LABORATORIES -1.9% 10.7% 21.4%
MANKIND PHARMA -2.3% 0.1% NA
TORRENT PHARMACEUTICALS 1.6% 2% 61.8%
LUPIN 2.4% 2% 132.5%


SUPRIYA LIFESCIENCE Revenues
[BOM: 543434|NSE : SUPRIYA]

Y-o-Y

-13.04 %

5 Yr CAGR

13.49 %

Years Revenues % Change
Mar2023 ₹461 Cr
-13.04
Mar2022 ₹530 Cr
35.49
Mar2021 ₹391 Cr
25.53
Mar2020 ₹312 Cr
12.17
Mar2019 ₹278 Cr -


SUPRIYA LIFESCIENCE Operating Profit
[BOM: 543434|NSE : SUPRIYA]

Y-o-Y

-39.98 %

5 Yr CAGR

18.82 %

Years Operating Profit % Change
Mar2023 ₹128 Cr
-39.98
Mar2022 ₹214 Cr
23.59
Mar2021 ₹173 Cr
75.99
Mar2020 ₹98 Cr
52.69
Mar2019 ₹64 Cr -

Operating Margins
Y-o-Y

-30.96 %

5 Yr CAGR

4.70 %

Years Operating Margin% % Change
Mar2023 27.87%
-30.96
Mar2022 40.37%
-8.79
Mar2021 44.26%
40.20
Mar2020 31.57%
36.14
Mar2019 23.19% -

SUPRIYA LIFESCIENCE Profit After Tax
[BOM: 543434|NSE : SUPRIYA]

Y-o-Y

-40.81 %

5 Yr CAGR

22.87 %

Years Profit After Tax % Change
Mar2023 ₹90 Cr
-40.81
Mar2022 ₹152 Cr
22.83
Mar2021 ₹124 Cr
68.38
Mar2020 ₹73 Cr
86.19
Mar2019 ₹39 Cr -

PAT Margins
Y-o-Y

-32.56 %

5 Yr CAGR

9.13 %

Years PAT Margin(%) % Change
Mar2023 17.4 %
-32.56
Mar2022 25.8 %
-10.04
Mar2021 28.68 %
40.52
Mar2020 20.41 %
66.34
Mar2019 12.27 % -

SUPRIYA LIFESCIENCE Earnings Per Share (EPS)
[BOM: 543434|NSE : SUPRIYA]

Y-o-Y

-40.83 %

5 Yr CAGR

-19.77 %

Years EPS % Change
Mar2023 ₹11
-40.83
Mar2022 ₹19
11.66
Mar2021 ₹17
-66.32
Mar2020 ₹50
86.22
Mar2019 ₹27 -

SUPRIYA LIFESCIENCE Return on Capital Employed (ROCE)
[BOM: 543434|NSE : SUPRIYA]

Y-o-Y

-56.81 %

5 Yr CAGR

-15.39 %

Years ROCE % Change
Mar2023 18.72%
-56.81
Mar2022 43.34%
-27.91
Mar2021 60.12%
21.04
Mar2020 49.67%
36.01
Mar2019 36.52% -

SUPRIYA LIFESCIENCE Share Price vs Sensex

Current Share Price : ₹410.2
Current MarketCap: ₹ 3,301.7 Cr
Updated EOD on :May 03,2024

Share Price Returns(%) 1 Week 1 Month 1 Year
SUPRIYA LIFESCIENCE

-0.1%

15.3%

93.1%

SENSEX

-0.6%

0.3%

21.8%

SUPRIYA LIFESCIENCE related INDICES

BSE Indices1W1M1Y
S&P BSE MIDSMALLCAP 1.4% 8.6% 66.5%
S&P BSE HEALTHCARE 0.8% 1.5% 55.8%
S&P BSE ALLCAP 0.4% 3.7% 40%
S&P BSE SMALL CAP 0.2% 9.3% 64.7%
No NSE index found

You may also like the below Video Courses


FAQ about SUPRIYA LIFESCIENCE Financials


How the annual revenues of SUPRIYA LIFESCIENCE have changed ?

The Revenues of SUPRIYA LIFESCIENCE have decreased by -13.04% YoY .

How the Earnings per Share (EPS) of SUPRIYA LIFESCIENCE have changed?

The Earnings Per Share (EPS) of SUPRIYA LIFESCIENCE has decreased by -40.83 % YoY .